Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer
Status:
Completed
Trial end date:
2008-01-09
Target enrollment:
Participant gender:
Summary
This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream
mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer
patients for three dosing schedules of lapatinib.